ELOVL6 is an endoplasmic reticulum-bound fatty acid elongase that catalyzes the rate-limiting step of long-chain fatty acid elongation, adding two carbons per cycle with highest activity toward C16:0 substrates 1. The enzyme preferentially elongates saturated and monounsaturated fatty acids with 12-16 carbons, serving as a precursor for membrane lipids and lipid mediators 2. ELOVL6 expression is transcriptionally regulated by the synergistic action of ChR4 and SREBP-1c in response to glucose and insulin 2, and is controlled by diet, oxidative stress, and circadian rhythms 1. ELOVL6 dysfunction associates with multiple diseases. In inflammatory skin disease, reduced m6A modification destabilizes ELOVL6 mRNA, increasing palmitic acid accumulation and neutrophil chemotaxis 3. In hepatocellular carcinoma, mitochondrial fission-driven ELOVL6 upregulation promotes de novo lipogenesis and tumor progression 4. In pancreatic cancer, c-MYC-regulated ELOVL6 supports tumor proliferation and chemoresistance; ELOVL6 inhibition enhances Abraxane sensitivity and suppresses tumor growth 5. Notably, ELOVL6 knockout mice show resistance to diet-induced insulin resistance despite obesity 6, suggesting therapeutic potential in metabolic disease. ELOVL6 is also implicated in kidney disease, epilepsy, pulmonary fibrosis, and glioblastoma 17, positioning it as a promising therapeutic target.